Mining Cholesterol Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mining Cholesterol

EVR 340.15

+3.1%

Dec 9 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: E. Charters	1/31/2007 10:54:31 AM
	of 356

depmed.ualberta.ca The first (successful) chemo for any disease group was the use of sulfa drugs, if we discount using mercury for syphilis. I am not sure that was chemo so much as chemical. Chemo seeks to alter the chemistry of the body per se, making sometimes localized environment toxic to certain cells and not to others, whereas mercury was designed to only be toxic to the pathogen per se. Many substances regress human tumours in animals, not the least of them being the group of cell inter-messenger mediating, "gap junction" modifying substances being developed by several firms including PharmaGap bioscreening.net But the eternal question is will the effects transfer to humans? Human metabolism is much different from many animals including apes, as well as its resistance to drugs and diseases. For instance apes do not get AIDS from HIV. A few humans do not either (about 3% of North Americans are immune to AIDS and this group is the same that is immune to bubonic plague.) And will the effects in the human body continue until tumour eradication, or will resistance to the drug be developed by the highly adaptive cancer cells, as so often happens? So toxicity questions at the chemo levels necessary, and resistance patterns have to be answered in successive clinical trial phases, not to mention the level of individual reaction to the drug. depmed.ualberta.ca Toxicity in the case of DCA at the outset seems to have been solved, although I am not sure that this applies to levels needed to combat tumours. But second phase human trials will often reveal effects not seen in the Pfizer second phase failure of Torcetrapib EC<:-}

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next